Study of GATA-3 Expression in Breast Carcinoma in a Tertiary Care Hospital in Eastern India: GATA3 expression in breast carcinoma

Lahari Banik; Mallika Pal; Nabanita Mayur

doi:10.32768/abc.202294450-455

Lahari Banik ⁽¹⁾, Mallika Pal ⁽²⁾, Nabanita Mayur ⁽³⁾

(1) Department of Pathology, Nil Ratan Sircar Medical College & Hospital (NRSMCH), Kolkata, India,

(2) Department of Pathology, Nil Ratan Sircar Medical College & Hospital (NRSMCH), Kolkata, India,

(3) Department of Pathology, Nil Ratan Sircar Medical College & Hospital (NRSMCH), Kolkata, India

https://doi.org/10.32768/abc.202294450-455

Issue
Volume 9, Issue 4, November 2022

Submitted
May 18, 2022

Published
July 19, 2022

Keywords:

breast carcinoma, GATA3, immunohistochemical marker

PDF XML

Abstract

Background: Transcription factor GATA3 is a relatively new and specific biomarker for breast carcinoma that regulates luminal cell differentiation. However, further studies that elucidate its role and diagnostic utility in breast cancer is desired. Therefore, this study was conducted to assess GATA3 expression in breast carcinoma and determine its association with various known prognostic and predictive factors of breast carcinoma.

Methods: This is a cross-sectional, observational study where 110 breast carcinoma cases were examined histologically on H&E stained slides for routine parameters such as tumor morphological type and histologic grade.ER/PR/Her-2-neu/ki67 and GATA3 expression was determined using immunohistochemistry. All cases were assessed to determine the association of GATA3 with different established clinicopathological parameters in breast cancer such as patient age, axillary lymph node status, tumor grade, lymphovascular invasion, molecular subtype etc. The results were statistically analyzed and P value < 0.05 was considered to be significant.

Results: 97 cases (88.1%) expressed GATA3 and it was significantly associated with most of the established clinico-pathological parameters like family history of breast cancer, tumour size and histology grade, lymph node and margin status, presence of lymphovascular invasion and carcinoma in-situ component .GATA3 expression was also significantly associated with ER/PR/Her2neu/ki67 expression.

Conclusion: GATA3 expression is significantly associated with the different established clinicopathological parameters of breast cancer. Therefore, it may be considered as a relevant marker more routinely. Further studies of GATA3 in breast cancer may refine prognostic models, predict clinical outcomes and modify treatment guidelines in future

Full text article

Generated from XML file

References

Merika M, Stuart H. DNA-binding specificity of GATA family transcription factors. Mol Cell Biol 1993; 13:4011–4022. doi: 10.1128/MCB.13.7.3999.

Asselin-Labat ML, Sutherland KD, Barker H, Thomas R, Shackleton M, Forrest NC, et al. GATA-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation. Nat Cell Biol 2007; 9:201–209. doi: 10.1038/ncb1530.

Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl AcadSci U S A 2001;98:10869 – 74. doi: 10.1073/pnas.191367098.

Charafe-Jauffret E, Ginestier C, Monville F, Finetti P, Adélaïde J, Cervera N, et al. Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene 2006;25:2273 – 84. doi: 10.1038/sj.onc.1209254.

Mehra R, Varambally S, Ding L, Shen R, Sabel MS, Ghosh D, et al. Identification of GATA-3 as a breast cancer prognostic marker by global gene expression meta analysis. Cancer Res 2005;65:11259 – 64. doi: 10.1158/0008-5472.CAN-05-2495.

Usary J, Llaca V, Karaca G, Presswala S, Karaca M, He X, et al. Mutation of GATA-3 in human breast tumors. Oncogene. 2004;23:7669-7678. doi: 10.1038/sj.onc.1207966.

Arnold JM, Choong DY, Thompson ER; kConFab, Waddell N, Lindeman GJ, Visvader JE, et al. Frequent somatic mutations of GATA-3 in non-BRCA1/BRCA2 familial breast tumors, but not in BRCA1-, BRCA2- or sporadic breast tumors. Breast Cancer Res Treat. 2010;119:491-496. doi: 10.1007/s10549-008-0269-x.

Cimino-Mathews A, Subhawong AP, Illei PB, Sharma R, Halushka MK, Vang R, et al. GATA-3 expression in breast carcinoma: utility in triple-negative, sarcomatoid, and metastatic carcinomas. Hum Pathol. 2013;44:1341-1349. doi: 10.1016/j.humpath.2012.11.003.

Yoon NK, Maresh EL, Shen D, Elshimali Y, Apple S, Horvath S, et al. Higher levels of GATA-3 predict better survival in women with breast cancer. Hum Pathol. 2010 Dec;41(12):1794-801. doi: 10.1016/j.humpath.2010.06.010.

Lakhani SR, Ellis LO, Schnitt SJ, Tan PH, van de Vijver MJ. Tumors of the breast in World Health Organization classification of tumors. Pathology and genetics of tumors of breast and female genital organs. 4th ed. Lyon: IARC Press; 2012. p. 8.

Ellis IO, Reis-Filho JS, Simpson JF, Decker T. Invasive breast carcinoma: introduction and general features in World Health Organization classification of tumors. 4th ed. Lyon: IARC Press; 2012. p. 19.

Gujam FJ, Going JJ, Edwards J, Mohammed ZM, McMillan DC. The role of lymphatic and blood vessel invasion in predicting survival and methods of detection in patients with primary operable breast cancer. Crit Rev Oncol Hematol 2014; 89:231–241. doi: 10.1016/j.critrevonc.2013.08.014.

Allred DC. Problems and solutions in the evaluation of hormone receptors in breast cancer. J Clin Oncol. 2008;26(15):2433-2435. doi: 10.1200/JCO.2007.15.7800.

Wolff A, Hammond M, Hicks D, Dowsett M, McShane L, Allison K, et al. Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. Archives of Pathology & Laboratory Medicine. 2014;138:241-256. doi: 10.1200/JCO.2013.50.9984.

Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ. Strategies for subtypes − dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer. Ann Oncol 2013; 22:1736–1740. doi: 10.1093/annonc/mdr304.

Agarwal H, Babu S, Rana C, Kumar M, Singhai A, Shankhwar SN, et al. Diagnostic utility of GATA-3 immunohistochemical expression in urothelial carcinoma. Indian J Pathol Microbiol 2019;62:244-50. Available from: https://www.ijpmonline.org/text.asp?2019/62/2/244/255808

Ismail A, Khalifa S, Saied E, El-Tamamy M. Immunohistochemical study of GATA-3 expression versus estrogen and progesterone receptor in invasive mammary carcinomas. Kasr Al Ainy Medical Journal 2018, 24:40–46. Available from: http://www.kamj.eg.net/text.asp?2018/24/1/40/233107

Albergaria A, Paredes J, Sousa B, Milanezi F, Carneiro V, Bastos J, et al. Expression of FOXA1 and GATA-3 in breast cancer: the prognostic significance in hormone receptor-negative tumours. Breast Cancer Res 2009; 11:R40. doi: 10.1186/bcr2327.

David Voduc, Maggie Cheang, and Torsten Nielsen. GATA-3 Expression in Breast Cancer Has a Strong Association with Estrogen Receptor but Lacks Independent Prognostic Value. Cancer Epidemiol Biomarkers Prev 2008;17(2).February 2008. doi: 10.1158/1055-9965.EPI-06-1090.

Yan W, Cao QJ, Arenas RB, Bentley B, Shao R. GATA-3 inhibits breast cancer metastasis through the reversal of epithelial-mesenchymal transition. The Journal of biological chemistry, (2010). 285(18), 14042–14051. doi:10.1074/jbc.M110.105262.

Jiang YZ, Yu KD, Zuo WJ, Peng WT, Shao ZM. GATA-3 mutations define a unique subtype of luminal-like breast cancer with improved survival. Cancer 2014; 120:1329–1337. doi: 10.1002/cncr.28566.

Yildirim E, Bektas S, Gundogar O, Findik D, Alcicek S, Erdogan KO, et al. The Relationship of GATA-3 and Ki-67 With Histopathological Prognostic Parameters, Locoregional Recurrence and Disease-free Survival in Invasive Ductal Carcinoma of the Breast. Anticancer Research Oct 2020, 40 (10) 5649-5657; doi: 10.21873/anticanres.14578.

Authors

Lahari Banik

Department of Pathology, Nil Ratan Sircar Medical College & Hospital (NRSMCH), Kolkata

https://orcid.org/0000-0003-3950-3724

laharibanik@gmail.com (Primary Contact)

Mallika Pal

Department of Pathology, Nil Ratan Sircar Medical College & Hospital (NRSMCH), Kolkata

https://orcid.org/0000-0003-3308-467X

Nabanita Mayur

Department of Pathology, Nil Ratan Sircar Medical College & Hospital (NRSMCH), Kolkata

https://orcid.org/0000-0003-0824-2488

Banik L, Pal M, Mayur N. Study of GATA-3 Expression in Breast Carcinoma in a Tertiary Care Hospital in Eastern India: GATA3 expression in breast carcinoma. Arch Breast Cancer [Internet]. 2022 Jul. 19 [cited 2024 Oct. 30];9(4):450-5. Available from: https://archbreastcancer.com/index.php/abc/article/view/593

Download Citation

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Copyright©. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International License, which permits copy and redistribution of the material in any medium or format or adapt, remix, transform, and build upon the material for any purpose, except for commercial purposes.

INTRODUCTION

Transcription factor GATA-3 binds to the DNA consensus sequence (A/T) GATA (A/G) 1 and plays a crucial role at multiple stages of breast development including luminal cell differentiation. 2 Therefore, GATA-3 dysregulation has been implicated in the pathogenesis of breast cancer. GATA-3 expression has been detected in the luminal breast cancer subtypes 3 4 5 , and somatic mutations of GATA-3 have been identified in ER-positive breast carcinomas. 6 7 GATA-3 shows promise as a sensitive and relatively specific marker for breast cancer as its expression is retained in "estrogen/progesterone receptor loss" metastases of breast carcinoma. 8 Several studies have also shown that higher levels of GATA-3 are associated with better survival in breast cancer 9 , making it a biomarker with potential independent prognostic value. Considering the relative paucity of studies aimed at understanding the role of GATA-3 in breast carcinoma in India, this study was conducted to detect GATA-3 expression using immunohistochemistry and determine its association with the different established prognostic parameters of breast carcinoma such as the histologic grade, morphological and molecular subtypes of tumor.

MATERIALS AND METHODS

This cross-sectional, observational study was conducted in the Department of Pathology, NRSMCH, Kolkata on 110 breast cancer patients who underwent surgery between February 2019 and July 2020 and gave consent for the study. Relevant history and clinical findings were noted. Formalin-fixed and paraffin-embedded tissue blocks were cut at 4μm thickness, stained with haematoxylin and eosin and examined for routine microscopic findings such as tumor morphological type 10 (Figure 1).

RESULTS

Out

GATA-3 Expression in breast carcinoma

Out of 97 cases positive for GATA-3 immunostaining, 35% cases were weak positive (score 2), 35% moderately positive (score 3) and 30% strong positive (score 4) for GATA-3.

GATA-3 Expression and clinical parameters

GATA-3 expression was not significantly associated with age (P=0.539), sex (P=0.358), tumor laterality (P=0.797), history of menopause (P=0.740), history of breast feeding (P=0.216) and history of chemotherapy (P=0.143). Interestingly, a significant association was found between GATA-3 expression and family history of breast carcinoma with lower expression of GATA-3 in cases with positive family history (P=0.019), although this analysis might have been compromised by the small number of family history positive cases (Table 2).

GATA-3 Expression and histological parameters

GATA-3 expression was significantly lower with larger tumor size (P=0.002), number of axillary lymph nodes involved (P=0.014), higher histological grade (P=0.014), presence of lymphovascular invasion (P=0.007), in-situ carcinoma component (P=0.017) and positive margins (P=0.007) (Table 3). However, GATA-3 expression was not significantly associated with the tumor morphological type (P=0.063).

GATA-3 Expression and immunohistochemical parameters

GATA 3 expression was significantly associated with ER/PR/HER2neu and ki67 expression with P value<0.001 for each variable. Higher GATA-3 expression was noted in positive ER/PR and low ki67 cases while lower expression was seen in Her-2-neu positive and triple negative cases (Table 4).

DISCUSSION

In this study, 97 out of 110 breast carcinoma cases (88.1%) expressed GATA-3. No statistically significant association of GATA-3 was found with age and sex of patient, tumor laterality, history of menopause, breast-feeding or chemotherapy. These findings corroborate the findings of the study of Ismail et al. 11 where nuclear expression of GATA-3 was detected in 36 (72%) cases and no association was found between GATA-3 expression and the age of the patients or tumor laterality. However, in our study, there was statistically significant lower expression of GATA-3 in the six cases (5.5%) with a positive family history (P=0.019).

In our study, 92 cases (83.6%) were diagnosed as invasive ductal carcinoma, no special type (IDCNST) and no significant association was found between GATA-3 expression and the morphological subtype of breast cancer (P=0.063). This is also similar to the study of Ismail et al. 11 where GATA-3 expression between cases of invasive ductal and lobular carcinoma breast was statistically insignificant (t=0.625).

Similar to the study by Albergaria et al. 18 and Voduc et al. 12 in our study, reduced GATA-3 expression was found in higher histological grade 3. GATA-3 expression was significantly associated with tumor grades (P<0.001), CIS (P=0.017) and LVI (P=0.007). All the cases with higher GATA-3 expression had uninvolved margin status while the cases with lower expression of GATA-3 had a statistically significant positive margin involvement (P=0.007). This may be related to the fact that GATA-3 is associated with reversal of epithelialmesenchymal transition and inhibits tumor metastasis. 13 It was seen that with an increase in the tumor size, there was reduced expression of GATA-3 (P=0.002). This finding corroborates the findings of the study of Mehra et al. 5 who found low GATA-3 expression was associated with larger tumor size (P=0.03). A significant association was found between GATA-3 expression and pN in our study (P=0.014) unlike the study of Voduc et al. 12 where there was no significant association between GATA-3 and lymph node status (Pearson chi-square test, P=0.47).

In our study, a significant association was found between expression of GATA-3 and the molecular types of breast cancer (P<0.001) with higher GATA-3 expression in the luminal subtypes and lower GATA-3 expression in the triple negative cases. A study by Ismail et al. 17 through the analysis of KW test demonstrated a significant association between GATA-3 expression in both luminal A and B-HER2-negative tumors when compared with GATA-3 expression in the triple-negative subtype. The same finding was reported by Jiang et al. 14 These observations agree with the hypothesis that GATA-3 mutations might be important in the aetiology of luminal-like breast cancers.

Individually, GATA-3 expression showed a significant association with ER, PR and Her-2-neu expression with P-value<0.001 in all cases. More cases of triple negative breast cancer were in the group that expressed low levels of GATA-3 and a significant association was found between the two in this study (P=<0.001). A high Ki-67value was found in all cases with low GATA-3 expression and a low ki67 value was observed for the majority of GATA-3-Grade 3 tumors. This finding is consistent with the study of Yildirim et al. 15 which revealed that GATA-3 has an inverse relationship with Ki-67. There was a significant association of GATA 3 expression with the ki67 status in the Grade 2 tumors (P<0.001).

Limitations

We have inferred statistical significance on the basis of the chi-square test. However, the trends are to be interpreted as only preliminary in view of the limited numbers in some of the cross-tabulation categories. Moreover, as no data on follow-up was available, the prognostic significance of GATA-3 in breast carcinoma could not be assessed.

CONCLUSION

GATA-3 is expressed in most cases of breast carcinoma. GATA-3 expression is significantly associated with different known prognostic factors in breast cancer such as the size and histology grade of tumor, axillary lymph node status, LVI, CIS and the molecular subtypes of breast cancer including ki67 index. GATA-3 expression was higher in the luminal subtypes and lower in the triple negative cases. Ki-67 was high in all low GATA-3 expressing tumors. Further studies on GATA-3 could be undertaken to assess its potential to predict prognosis in breast carcinoma or develop novel therapeutic approaches in the future.

CONFLICTS OF INTEREST

None.

ETHICAL CONSIDERATIONS:

Institutional Ethics Committee approval no/NMC/10018; dated: 08-01-19.

FUNDING

None.

Expression of GATA-3 by IHC (A) GATA-3 Group 1 (1X1) = Negative [40X] ; (B) GATA-3 Group 2 (2X1) = weakly + [40X] ; (C) GATA-3 Group 3 (4X2) = moderately + [40X] ; (D) GATA-3 Group 3 (4X3) = strongly + [40X].

Read Counter : 805 Download : 38

Share Now

Study of GATA-3 Expression in Breast Carcinoma in a Tertiary Care Hospital in Eastern India GATA3 expression in breast carcinoma

Abstract

Full text article

References

Authors

Similar Articles

Important Links

Contact Info

Article Sidebar

Abstract

Full text article

References

Authors

Article Details

Similar Articles

Important Links

Contact Info